Bladder cancer spreads at different speeds depending on the type of bladder cancer you have. Urothelial bladder cancer is slow to spread, while other types are much faster. Urothelial bladder ...

Way back in March and April, I was diagnosed with bladder and prostate cancer, and then it spread into the spine and the pelvis, so it was quite aggressive.' In an urgent warning to listeners ...

There are several different treatment options available for bladder cancer. One of these is immunotherapy, a type of treatment that works to boost your immune system’s response to the cancer.

ABOUT 55,000 new prostate cancer cases are recorded every year in the UK. Bladder cancer is less common, with around 10,500 new cases. For both types, cancer can start in one area of the body and ...

Immune-mediated rash or dermatitis occurred in 1.8% ... is indicated for the treatment of adult patients with muscle-invasive bladder cancer (MIBC). Please see Full Prescribing Information ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

Deaths among hospitalized patients with bladder cancer in the United States significantly increased from 4.5% in 2008 to 4.9% in 2021, driven by increased mortality among specific subgroups, ...

The FDA has approved Imfinzi (durvalumab) as neoadjuvant and adjuvant treatment in patients with muscle-invasive bladder cancer.

Two doses of a simple tuberculosis vaccination after surgery helps the immune system fight cancer cells and could greatly improve patient outcomes for the most common type of bladder cancer, according ...

The approval follows the December 2024 priority review designation for this perioperative immunotherapy regimen for patients fighting muscle-invasive bladder cancer (MIBC).

Immune checkpoint inhibitors have shown a survival benefit in patients with metastatic urothelial cancer, so investigators trialed neoadjuvant nivolumab and ipilimumab in patients with muscle-invasive ...

“Today’s approval for Imfinzi represents a paradigm shift, bringing the first perioperative immunotherapy to patients in the US with muscle-invasive bladder cancer and addressing a significant ...